AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals.
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Single case report describes durable response to nivolumab in relapsed ALK+ large B-cell lymphoma
Can a common immunotherapy drug help a rare, aggressive lymphoma?
A case report describes one adult patient with stage IV, relapsed/refractory ALK+ large B-cell lymphoma who received off-label nivolumab.
A rare, aggressive lymphoma that failed four treatments responded rapidly to an immunotherapy drug not approved for this cancer, offering ho…
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Post hoc analysis links TMB ≥9 or BRAF-V600E to longer PFS with chemo-nivolumab in MSS/pMMR mCRC
Could two simple blood tests help predict which colon cancer patients benefit from immunotherapy?
A post hoc analysis of the METIMMOX RCT in patients with metastatic MSS/pMMR colorectal cancer found that in the experimental arm (alternati…
Two simple blood tests and tumor markers can predict which colon cancer patients live longer on immunotherapy combined with chemotherapy.
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…